EYPT - EyePoint OcuMension's eye implant therapy implant Yutiq gets approval in China

China's National Medical Products Administration approved EyePoint Pharmaceuticals (NASDAQ:EYPT) and OcuMension Therapeutics' (OTCPK:OCUTF) intravitreal implant Yutiq to treat chronic non-infectious uveitis affecting the posterior segment of the eye. Uveitis is a type of eye inflammation. Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg is the first drug approved for commercialization in China based entirely on real-world data. In September 2020, OcuMension had launched the real-world study of the treatment in China, the companies said in a June 21 press release. Yutiq is also OcuMension's first drug approved for commercial use. Yutiq is already approved in the U.S. with EyePoint having development and commercialization rights for the therapy to treat non-infectious uveitis affecting the posterior segment of the eye in the Americas and in Asia.

For further details see:

EyePoint, OcuMension's eye implant therapy implant Yutiq gets approval in China